Binding of drugs to plasma proteins is often a significant determinant of the pharmacological properties of antimicrobial agents. The proportional reduction in the in vitro activity of antimicrobial agents highly bound to plasma proteins in media supplemented with serum has been noted for several beta-lactam and other compounds (4, 19) . Protein binding may influence the pharmacokinetics of non-protein-bound (unbound) as well as total (bound and unbound) drug by affecting the rate of excretion or altering the rate and extent of drug distribution from blood to tissues (3, 7, 18) .
The extent of binding of drugs to protein is determined by drug and protein concentration, the affinity of drug for the protein, and the number of binding sites on each molecule of protein (9) . For some drugs, clinically achievable concentrations in vivo may saturate binding sites on plasma proteins, resulting in a free fraction of drug larger than that observed at lower drug concentrations (9) . As drug concentrations decline in vivo due to drug excretion, the free-fraction declines and approaches a constant value. This nonlinearity in in vivo plasma protein binding may affect the decline in total and unbound drug concentrations because of the dependence of the volume of distribution and clearance of total and unbound drug on the extent of plasma protein binding (3, 7, 17) .
Cefonicid is a cephalosporin antibiotic highly bound to plasma proteins (approximately 96% at 100 ,ug/ml) (5) . We have previously demonstrated saturable serum protein binding in vitro, with the fraction bound to protein decreasing to as low as 67% with drug concentrations exceeding 400 ,ug/ml (W. C. Shyu, M. N. Dudley Normal saline was used to flush intravenous catheters to maintain patency. Urine was collected, the volume was measured, and a sample was saved during the following intervals: 0 to 30, 31 to 60, 61 to 90, and 91 to 120 min and 2 to 2.5, 2.5 to 3, 3 to 3.5, 3.5 to 4, 4 to 5, 5 to 6, 6 to 8, 8 to 10, 10 to 12, 12 to 24, 24 to 36, and 36 to 48 h after administration of the dose. Urine was frozen at -80°C until the assay.
Unbound drug. Blood samples from volunteers were allowed to clot and centrifuged, and the serum was harvested. Unbound drug was immediately separated by ultrafiltration of a portion of each serum sample with an MPS-1 unit with a YMT membrane (Amicon Corp., Danvers, Mass.) through centrifugation at 1,700 x g for 15 min at 37°C. Analysis of binding properties in preliminary experiments demonstrated that binding of cefonicid to serum proteins was rapid and not time dependent. Validation studies also showed no degradation of cefonicid after incubation at 37°C in serum (data not shown). Binding to the YMT membrane was checked by ultrafiltration of an aqueous standard; complete recovery of drug was observed in the ultrafiltrate. Serum and ultrafiltrate were stored at -80°C until the assay.
Assay. Cefonicid concentrations in serum, serum ultrafiltrate, and urine were measured by microbiological assay with Bacillus subtilis (Difco Laboratories, Detroit, Mich.)-seeded agar plates and paper disks spotted with 15 ,ul of sample or standard. Standards (12.5 to 400 pLg/ml) for assay of total cefonicid concentrations in serum were prepared from pooled serum collected from drug-free healthy volunteers. Standards for the assay (1.25 to 50 p.g/ml) of unbound serum and urine cefonicid concentrations were prepared in Sorenson phosphate buffer. The lower limit of assay sensitivity was 12 pLg/ml in serum and 0.8 ,ug/ml in buffer.
Standard curves of the zone size versus the natural logarithm of the drug concentration were linear in the ranges listed above with correlation coefficient (r) values greater than 0.99 on all days. The within-day coefficient of variation for the assay ranged between 6 and 15% for serum standards (n = 6) and 10 to 17% for buffer standards (n = 15). Drug content in the ultrafiltrate below the limit of sensitivity of the microbiologial assay was assayed with high-pressure liquid chromatography (15) .
Data analysis. The number of binding sites per mole of albumin and the affinity of cefonicid for binding sites was determined by nonlinear regression (14) (1) where r is the number of moles of drug bound to moles of protein, n is the number of binding sites of a given type per mole of protein, ka is the association constant between drug and protein, and Df is the molar concentration of free drug (9) .
Total and unbound serum concentration versus time data were analyzed by noncompartmental pharmacokinetic methods (8) . The time-averaged free fraction of cefonicid in the body (fp) after the dose was determined by (13) -AUCU fP AUCT (2) where AUCU and AUCT are the areas under the serum concentration-versus-time curve from time 0 to infinity for unbound and total drug, respectively. Areas were calculated by the linear trapezoidal rule. The total body clearance of total (CLT) and unbound (CLU) drug was determined by dose/AUCT or dose/AUCU, respectively. 
where AUMCT is the area under the first moment of the plasma concentration of total drug-versus-time curve from time 0 to infinity (calculated using the linear trapezoidal rule) and t' is the time of drug infusion. The decline in mean total and unbound serum cefonicid concentration is depicted in Fig. 2 . Total serum drug concentrations were high, with a mean ± SD peak concentration of 341 ± 44.3 ,ug/ml immediately after dose administration. After a rapid distribution phase, total serum concentrations declined slowly, with a mean ± SD serum elimination half-life of 4.1 ± 0.8 h. In contrast, unbound serum concentrations declined rapidly and in a prolonged nonlinear manner; the mean ± SD peak unbound serum cefonicid concentration was 46.2 ± 22.9 after administration and declined to 12.8 + 2.1 ,ug/ml within 1 h after administration. At 12 h, serum concentrations were less than 1 ,ug/ml in all subjects.
The pharmacokinetic analysis of total and unbound serum cefonicid concentrations is summarized in Table 1 . Values of total body and renal clearance and volume of distribution at steady state were substantially greater for unbound drug than for total drug.
The renal clearance of total and unbound cefonicid during 10 time intervals is shown in Fig. 3 . The renal clearance of unbound cefonicid increased with time, with mean ± SD values increasing from 5.7 ± 2.1 ml/min per kg during the first hour after dosing to 10.8 ± 1.6 ml/min per kg between 8 and 10 h postadministration. The change in the renal clearance of unbound cefonicid with time was statistically significant (P < 0.02, analysis of variance). In contrast, the renal clearance of total cefonicid during these intervals did not vary with time (P > 0.05, analysis of variance; Fig. 3 Sciences, 1983 ). The affinity of cefonicid to serum proteins in vitro and in vivo is higher than that reported for ceforanide (20) , methicillin, and nafcillin (10); these drugs do not appear to have concentration-dependent protein binding at serum concentrations observed in humans. However, the affinity of cefonicid for plasma proteins was similar to that observed for ceftriaxone, a drug showing concentration-dependent binding similar to that of cefonicid (21) . The distribution and excretion rate of total cefonicid was similar to that reported by others using smaller or similar doses (5) . In contrast to total serum concentrations, unbound serum cefonicid concentrations declined rapidly and in parallel with changes in the free fraction of drug in vivo. Although unbound drug concentrations could be measured up to 12 h in only three subjects, the half-life of the terminal slopes of unbound and total drug concentration-versus-time curves 8 to 12 h postadministration (3.5 ± 0.2 h for unbound drug versus 4.1 ± 0.8 h for total drug) appeared to become parallel (Fig. 2) . This is consistent with the simulations performed by 0ie et al. (17) . The large change in the free fraction of unbound cefonicid (approximately an eightfold reduction over a 12-h period) resulted in a statistically significant increase in the renal clearance of unbound cefonicid during that time interval.
Despite similar binding characteristics, the effects of saturable in vivo serum protein binding on the renal excretion of unbound and total cefonicid are in sharp contrast to that observed for ceftriaxone. Stoekel et al. (21) demonstrated no change in unbound renal ceftriaxone clearance but a statistically significant decrease in total ceftriaxone renal clearance with time. The differences in the time dependence of the renal excretion rate of these drugs may be explained by the models of renal clearance proposed by Levy (11) and Dudley and Nightingale (3) . Assuming that the renal tubular secretion rate of cephalosporins is a function of the total drug concentration, the renal clearance of total drug may be described by
where F is the fraction of drug reabsorbed, GFR is the glomerular filtration rate, fu is the fraction unbound, and CLs is the renal secretion clearance or (Q x CL,)I(Q + CLI, where Q is the plasma flow to renal tubular secretion sites, and CL1 is the intrinsic renal secretion clearance referenced to total drug (11 (9) Therefore, reduction in the free fraction (fu), which occurs with time after dosing (Fig. 1) , would be expected to result in little change in total renal clearance and an increase in unbound renal clearance; this is consistent with Fig. 3 (1) , it is unlikely that the total duration of bactericidal activity was sufficient to eradicate valve infection (6) . This experience and the present study suggest that more frequent administration of cefonicid is necessary 
